Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8147969 | 0.84 | NR4A2 (0.43) | NR4A2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29786977 | 0.79 | LMNA (0.50) | NR4A2MAPTKMT2ASOS2MAP3K14 | |
| SCHEMBL1317870 | 0.79 | LMNA (0.50) | NR4A2MAPTKMT2ASOS2MAP3K14 | |
| SCHEMBL29024926 | 0.76 | CTDSP1 (0.50) | MAPTMEN1KMT2ASMN1; SMN2ATM | |
| SCHEMBL17398192 | 0.76 | NR4A2 (0.43) | NR4A2MAPTSOS2MAP3K14CDC7 | |
| SCHEMBL29987789 | 0.76 | MAP4K4 (0.54) | NR4A2MAPTSOS2MAP3K14CDC7 | |
| SCHEMBL2757280 | 0.76 | CYP2A6 (0.53) | NR4A2MAPTSOS2MAP3K14CDC7 | |
| SCHEMBL3735578 | 0.76 | CYP2A6 (0.44) | MEN1KMT2AALDH1A1TDP1CYP2A6 | |
| SCHEMBL582930 | 0.76 | PLAU (0.56) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL30497136 | 0.76 | PLAU (0.56) | MAPTMEN1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4558479-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-05-28 | — | — | EP | disclosed |
| CN-119546572-A | Novel naphthyl and isoquinoline sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-02-28 | — | — | CN | disclosed |
| WO-2025016273-A1 | ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USES OF ISOQUINOLINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION | 拜西欧斯（北京）生物技术有限公司 | 2025-01-23 | — | — | WO | disclosed |
| EP-3935042-B1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC (KR) | 2024-08-28 | — | — | EP | disclosed |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | NOBO MEDICINE INC. (KR) | 2024-08-27 | — | — | US | disclosed |
| WO-2024017858-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-25 | — | — | WO | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-7772180-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772180-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-19 | — | — | US | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-11-05 | — | — | US | disclosed |
| WO-2009129109-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2008060927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119461-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | NR4A2 4009/4885MAPT 4108/4885MEN1 4801/4885 |
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | NR4A2 3845/4885MAPT 2044/4885MEN1 3373/4885 |
| US-20090285773-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | NR4A2 4009/4885MAPT 4108/4885MEN1 4801/4885 |
| US-12071412-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | NR4A2 3845/4885MAPT 2044/4885MEN1 3373/4885 |
| US-20260027104-A1 | NOVEL NAPHTHYL AND ISOQUINOLINE SULFONAMIDE DERIVATIVES | CBR3, HAX1, CBR1 | NR4A2 100/4885MAPT 4870/4885MEN1 3743/4885 |
| US-20090274652-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | NR4A2 4009/4885MAPT 4108/4885MEN1 4801/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | NR4A2 3845/4885MAPT 2044/4885MEN1 3373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.